BioRestorative Therapies stock analysis
Want to see BRTX full AI Analyst Report?
BioRestorative Therapies (BRTX) Stock Price & Analysis
BRTX Stock Chart & Stats
- Day’s Range
- $1.45 - $1.56
- 52-Week Range
- $1.28 - $28.98
- Previous Close
- $1.50
- Volume
- N/A
- Average Volume (3M)
- 31.92K
- Market Cap
- $2.06M
- Enterprise Value
- $1.27M
- Total Cash (Recent Filing)
- $3.59M
- Total Debt (Recent Filing)
- $34.52K
- Price to Earnings (P/E)
- ―
- Beta
- 0.99
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Minimal Leverage
Effectively no debt limits interest obligations and reduces balance-sheet pressure while the company funds development. This provides some financial flexibility compared with a leveraged biotech, although it does not eliminate the need for external capital.
Solid Gross Margin
A roughly 63% gross margin indicates that the company’s reported revenue can generate meaningful value after direct costs. If revenue expands through successful commercialization, this margin profile could support operating leverage, though current expenses remain far higher than sales.
Board Governance Strengthened
Adding an independent director and reconstituting key committees strengthens formal oversight during a period of leadership change. Better governance can improve accountability, board scrutiny, and investor confidence as the company manages clinical, regulatory, and financing decisions.
Bears Say
Persistent Cash Burn
Persistent and worsening cash outflows show that operations are not self-funding and that external financing remains necessary. Continued burn can constrain research execution, increase dilution risk, and reduce the company’s ability to withstand delays in clinical or commercial progress.
Shrinking Revenue And Deep Losses
Very small and declining revenue provides little support for the company’s cost base, while the extremely negative net margin shows that it remains far from breakeven. This weak earnings foundation limits internally generated capital and makes future progress dependent on successful development or financing.
Nasdaq Compliance Risk
Failure to file a required quarterly report creates a durable compliance and reporting overhang, with potential consequences for continued Nasdaq listing. Management must devote resources to remediation, while any prolonged uncertainty could hinder financing access and stakeholder confidence.
BRTX FAQ
What was BioRestorative Therapies’s price range in the past 12 months?
What is BioRestorative Therapies’s market cap?
When is BioRestorative Therapies’s upcoming earnings report date?
How were BioRestorative Therapies’s earnings last quarter?
Is BioRestorative Therapies overvalued?
Does BioRestorative Therapies pay dividends?
What is BioRestorative Therapies’s EPS estimate?
How many shares outstanding does BioRestorative Therapies have?
What happened to BioRestorative Therapies’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioRestorative Therapies?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BioRestorative Therapies
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Katharyn Field
- Employees
- 14
- Website
- www.biorestorative.com
- Address
- 40 Marcus Drive, Melville, NY, 11747, US
BioRestorative Therapies (BRTX) Earnings & Revenues
BRTX Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted significant milestones in the company's clinical and commercial development, such as the Fast Track designation for BRTX-100 and a new patent for ThermoStem. However, these were counterbalanced by a sharp revenue decline and increased net loss compared to the previous year. Despite the financial setbacks, the overall sentiment is cautiously optimistic with strategic developments and a strengthened financial position.
View all BRTX earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |












